You are adding an alert for:
Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: